AHA

This channel contains news about the American Heart Association (AHA), including coverage of its annual meeting and guidelines. AHA is a leading resource for cardiology information, both consumer and professional.

Feature | AHA

American Heart Association Honors Distinguished Scientists at AHA22

November 9, 2022 — Seven awardees were honored during the American Heart Association Scientific Sessions (AHA 2022). The ...

November 09, 2022

New genomic therapies for cardiovascular disease are reaching the clinical trial stage, according to moderators of a session presented at the American Heart Association Annual Scientific Session (AHA2022).

News | AHA

Progress Reported on Clinical Trials of Genomic Profiling for Cardiovascular Disease at AHA 2022

November 8, 2022 — Genomic-based therapies for cardiovascular disease are emerging fast in research, and could soon be ...

November 08, 2022

Robert J. Mentz, M.D., Associate Professor of Medicine, Chief, Heart Failure Section, Associate Program Director, Duke Cardiology Fellowship, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, image copyright Robert J. Mentz

News | AHA

TRANSFORM-HF Trial Found No Difference in Effectiveness Between 2 Common Loop Diuretics

November 8, 2022 — After hospital discharge for heart failure, people treated with either loop diuretic medication ...

November 08, 2022

Julian D. Gillmore, M.D., Ph.D., Professor, University College London Centre for Amyloidosis, United Kingdom, image copyright University College London Centre for Amyloidosis

News | AHA

Novel Gene-Editing Therapy Shows Promise For Patients With Transthyretin Amyloid Cardiomyopathy

November 8, 2022 — A single IV infusion of NTLA-2001, a novel CRISPR/Cas9-based gene editing therapy, significantly ...

November 08, 2022

Clinical studies presented at the American Heart Association 2022 Scientific Sessions event demonstrate compelling diagnostic and health economic value of the Zio suite of products across a range of clinical applications

News | AHA

Results of Four Studies Demonstrating Clinical, Economic Value of iRhythm’s Product Portfolio Presented at American Heart Association ’22

November 8, 2022 — iRhythm Technologies, Inc., a leading cardiovascular diagnostics and digital healthcare solutions ...

November 08, 2022

Using coronary computed tomography angiography (CCTA) with HeartFlow’s FFRCT Analysis to evaluate suspected coronary artery disease (CAD) offers more accurate non-invasive diagnosis, fewer unnecessary tests, and higher confidence in identifying patients needing treatment

News | AHA

Late-Breaking Data Demonstrate AHA/ACC Guideline-Directed CCTA ± FFRCT Precision Pathway is Superior to Traditional Testing

November 7, 2022 — HeartFlow, Inc., the leader in revolutionizing precision heartcare, today announced new trial results ...

November 07, 2022

A new analysis of iRhythm’s mSToPS trial, presented at the American Heart Association, reveals that Zio XT provided high value from a health economic perspective

News | AHA

New Research Confirms that Zio by iRhythm Provides High Value From a Health Economic Perspective

November 7, 2022 — iRhythm Technologies, Inc., a leading cardiovascular diagnostics and digital healthcare solutions ...

November 07, 2022

Petr Ostadal, M.D., Ph.D., Professor of Medicine, Department of Cardiology, Na Homolce Hospital, Czech Republic. Image copyright Na Homolce Hospital

News | AHA

Early Use of ECMO devices Did Not Improve Outcomes in People With Cardiogenic Shock

November 7, 2022 — The immediate use of veno-arterial mechanical circulatory extracorporeal membrane oxygenation (ECMO) ...

November 07, 2022

The American Heart Association to enable a wide range of research with real-time data from acute care hospitals

News | Cardiogenic Shock

New Data Registry Collects Evidence in Cardiogenic Shock Patients

October 20, 2022 — Cardiogenic shock—a life threatening condition when a person’s heart can’t pump enough blood to meet ...

October 20, 2022

CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from its BrigHtn trial evaluating baxdrostat in patients with treatment-resistant hypertension as part of the late-breaking science session

News | Hypertension

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data for Baxdrostat in Treatment-Resistant Hypertension at the Upcoming 2022 American Heart Association Scientific Sessions

October 5, 2022 — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from ...

October 05, 2022

12 month data from The PRECISE Trial, the first global, prospective, randomized trial comparing diagnosis and evaluation pathways for stable chest pain, will be presented at the AHA 2022 Scientific Sessions.

News | AHA

HeartFlow Announces Late Breakers Presentation at the 2022 American Heart Association (AHA) Scientific Sessions

October 4, 2022 — HeartFlow, Inc., the leader in revolutionizing precision heart care, announced that the results of the ...

October 04, 2022

The stage is set for the American Heart Association (AHA) Scientific Sessions 2022, to be held November 5-7 at McCormick Place in Chicago, and virtually.

News | AHA

AHA Scientific Sessions 2022 Program, Late-breakers Announced

October 4, 2022 — The American Heart Association (AHA) Scientific Sessions 2022 is set for November 5-7 at McCormick ...

October 04, 2022

News | Cardiovascular Education

USPSTF Issues Statin Recommendation Statement

August 29, 2022 — The US Preventive Services Task Force (USPSTF) has issued a Recommendation Statement, relating to ...

August 29, 2022

It recently was announced that two leaders in cardiovascular disease science, research and education — the American Heart Association (AHA) and the Cardiovascular Research Foundation (CRF) — are joining forces, which will help strengthen and expand educational opportunities in cardiovascular disease and interventional therapies.

Blog | Cardiovascular Education

Educational Leaders Join Forces on Educational Opportunities

It recently was announced that two leaders in cardiovascular disease science, research and education — the American ...

August 23, 2022

In a detailed analysis of nearly 43 million people, ages 13 and older, who received at least one dose of a COVID-19 vaccine in England, the risk of myocarditis in unvaccinated individuals after COVID-19 infection was at least 11 times higher compared to people who developed myocarditis after receiving a COVID-19 vaccine or booster dose

News | Coronavirus (COVID-19)

Myocarditis Risk Significantly Higher After COVID-19 Infection vs. After a COVID-19 Vaccine

August 23, 2022 — In a detailed analysis of nearly 43 million people, ages 13 and older, who received at least one dose ...

August 23, 2022